We are live on ! Find out more
VPHM

VIROPHARMA INC
VPHM

Delisted

VPHM was delisted on the 23rd of January, 2014.

172 hedge funds and large institutions have $3.29B invested in VIROPHARMA INC in 2013 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 47 increasing their positions, 61 reducing their positions, and 69 closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more funds holding in top 10

Funds holding in top 10: 411 (+7)

14% more capital invested

Capital invested by funds: $2.87B → $3.29B (+$416M)

10% less funds holding

Funds holding: 191172 (-19)

23% less repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 61

25% less first-time investments, than exits

New positions opened: 52 | Existing positions closed: 69

57% less call options, than puts

Call options by funds: $67.1M | Put options by funds: $155M

Holders
172
Holders Change
-19
Holders Change %
-9.95%
% of All Funds
4.99%
Holding in Top 10
11
Holding in Top 10 Change
+7
Holding in Top 10 Change %
+175%
% of All Funds
0.32%
New
52
Increased
47
Reduced
61
Closed
69
Calls
$67.1M
Puts
$155M
Net Calls
-$87.5M
Net Calls Change
-$82.9M
Name Holding Trade Value Shares
Change
Change in
Stake
N
126
Nuveen
North Carolina
$569K +$2.33K +52 +0.5%
First Trust Advisors
127
First Trust Advisors
Illinois
$567K +$508K +11,370 New
AAM
128
Advisors Asset Management
Colorado
$548K -$54.9K -1,228 -10%
MSA
129
Mason Street Advisors
Wisconsin
$507K +$23.7K +529 +5%
GPCM
130
Granite Point Capital Management
Massachusetts
$499K +$447K +10,000 New
FFH
131
Fairfax Financial Holdings
Ontario, Canada
$498K +$447K +10,000 New
State of Wisconsin Investment Board
132
State of Wisconsin Investment Board
Wisconsin
$494K +$443K +9,900 New
HCM
133
Highbridge Capital Management
New York
$442K -$236K -5,283 -37%
KBC Group
134
KBC Group
Belgium
$425K
Los Angeles Capital Management
135
Los Angeles Capital Management
California
$388K
ProShare Advisors
136
ProShare Advisors
Maryland
$381K -$2.67M -59,753 -89%
WFM
137
Wilmington Funds Management
Delaware
$360K +$323K +7,224 New
AB
138
Amalgamated Bank
New York
$338K +$303K +6,771 New
AA
139
Ancora Advisors
Ohio
$334K +$300K +6,700 New
AIP
140
Ameritas Investment Partners
Nebraska
$287K +$5.41K +121 +2%
LOM
141
Loeb Offshore Management
New York
$283K -$1.11M -24,724 -81%
SB
142
Suntrust Banks
Georgia
$278K -$537 -12 -0.2%
RFC
143
Russell Frank Company
Washington
$266K -$8.45M -188,870 -97%
DTL
144
Dynamic Technology Lab
Singapore
$264K +$237K +5,303 New
BF
145
BOK Financial
Oklahoma
$231K -$64.9K -1,451 -24%
HIMCH
146
Hartford Investment Management Co (HIMCO)
Connecticut
$231K +$207K +4,634 New
Millennium Management
147
Millennium Management
New York
$205K -$2.07M -46,195 -92%
Canada Life
148
Canada Life
Manitoba, Canada
$186K +$166K +3,705 New
OA
149
OFI Advisors
Pennsylvania
$176K +$1.3K +29 +0.8%
PAM
150
Paradigm Asset Management
New York
$162K

VPHM Hedge Fund Activity: Q4 2013 in Review

172 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in VIROPHARMA INC (VPHM) for Q4 2013, worth a combined $3.29B — up 14% from $2.87B a quarter earlier.

Sellers outnumbered buyers: 69 funds closed out of VPHM and 52 opened new positions — a net loss of 17 holders — while 61 trimmed existing stakes and 47 added.

The largest buyer was Oxford Asset Management, opening a new position worth an estimated $137M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $220M sold.

  • 172 institutional investors held VIROPHARMA INC (VPHM) as of Q4 2013, down from 191 in Q3 2013.
  • Funds reported $3.29B of VIROPHARMA INC stock for Q4 2013, up 14% quarter-over-quarter.
  • 52 funds opened new VIROPHARMA INC positions in Q4 2013 and 69 closed out, a net change of -17 holders.
  • The largest VIROPHARMA INC buyer in Q4 2013 was Oxford Asset Management, an estimated $137M added.
  • The largest VIROPHARMA INC seller in Q4 2013 was Baker Bros. Advisors, an estimated $220M sold.

Based on aggregated 13F filings for Q4 2013.